Key facts
- This page summarizes Nitin Sood's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Aug 2023, 16:53.
Nitin Sood - 07 Aug 2023 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)
- Reporting relationship
- Chief Commercial Officer, MRD
- Issuer ticker
- ADPT
- Reported as of
- 07 Aug 2023
- Net transaction value
- -$107,318
- SEC form
- 4
- Accepted by SEC
- 08 Aug 2023, 16:53:22 UTC
- Prior SEC filing
- 08 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nitin Sood by Stacy L Taylor, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Nitin Sood filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 08 Aug 2023.
Change
- Previous filing in this sequence was filed on 08 Mar 2023.
- Current net transaction value: -$107,318.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADPT
transaction
Common Stock
Sale
- Transaction value
- $38,321
- Shares
- -5,652
- Change %
- -2.4%
- Price
- $6.78
- Shares after
- 225,358
- Date
- 07 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
ADPT
transaction
Common Stock
Sale
- Transaction value
- $68,997
- Shares
- -10,550
- Change %
- -4.7%
- Price
- $6.54
- Shares after
- 214,808
- Date
- 08 Aug 2023
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Footnote F2
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022.
Footnote F3
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $6.48 to $6.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.